Onyx Earnings Top Analysts’ Estimates on Medicine Sales

Onyx Pharmaceuticals Inc., a maker cancer drugs, reported a fourth-quarter loss that was less than analysts’ estimates as sales of newly approved therapies rose faster than expected.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.